The invention relates to an apparatus and method for performing Positive Expiratory Pressure (PEP) therapy. More particularly, this invention relates to a method and apparatus for performing PEP therapy alone or in conjunction with an aerosol delivery apparatus.
PEP therapy is used primarily in pulmonary secretion removal. Devices used to perform PEP therapy provide positive pressure during expiration. The patient or user exhales against a fixed orifice resistor and generates a pressure ranging approximately from 10-20 cm H2O. The resistance orifice is an important consideration and frequently is initially set by a physician, veterinarian, or a skilled practitioner in the art. An orifice that is too large may result in a short exhalation that will not produce proper expiratory pressure. An orifice that is too small may result in a longer expiratory phase that raises the pressure above approximately 20 cm H2O and ultimately increases the work of breathing.
During the exhalation phase of PEP therapy, the airway is splinted open by the pressure. This causes the movement of secretions from the peripheral airways into the larger airways where they can be expelled. PEP therapy usually lasts for about 10-20 minutes and is performed as required, generally 1-4 times per day. Typically, the patient performs 10-20 PEP breaths, removes the device from their mouth and follows this with a forceful exhalation. This final exhalation triggers a cough that loosens secretions.
Studies indicate that PEP therapy dilates the airways and improves the distribution of ventilation, resulting in a better deposition of an inhaled substance, such as, but not limited to, a medicine or remedy. As used herein, the term “aerosol delivery apparatus” means any apparatus capable of producing and/or delivering a substance, such as, but not limited to, a medicine, in a form suitable for inhalation by a patient and includes, without limitation, an aerosol holding chamber, nebulizer, spacer with integrated actuator, a dry powder inhaler, and a metered dose inhaler.
One aspect of the present invention is directed to a positive respiratory pressure apparatus including a patient respiratory system interface and a valve assembly in fluid communication with the patient respiratory system interface. The valve assembly has a valve configured to pass a fluid traveling in a predetermined direction from a first side to a second side of the valve, and a variable resistance bypass window positioned adjacent the valve and having a resistance to a fluid traveling in a direction opposed to the predetermined direction, where the variable resistance bypass window is continuously adjustable between a first fluid resistance and a second fluid resistance.
According to another aspect of the invention an apparatus is disclosed that is capable of performing positive expiratory pressure (PEP) therapy alone or in combination with providing a substance, generally in aerosol form. The apparatus includes a positive pressure (PP) valve having a continuously variable respiratory window. As used herein, the term respiratory is intended to encompass both inhalation and exhalation. Whether inhalation resistance or exhalation resistance is called for will be known to one skilled in the art. The valve may be located at or near the output end of an aerosol delivery apparatus. U.S. application Ser. No. 08/938,686 filed Sep. 26, 1997 in the name of Engelbreth et al. and Ser. No. 09/287,997 filed on Apr. 7, 1999 in the name of Schmidt et al. describe exemplary embodiments of an aerosol delivery apparatus and the disclosures of these references are incorporated herein by reference. Further, U.S. Pat. No. 4,470,412 to Nowacki et al., describing a spacer or expansion chamber, is additionally incorporated herein by reference. The aerosol delivery apparatus with the PP apparatus may be used alone or in combination with a mask or mouthpiece.
In one embodiment, the PP apparatus is associated with a mask. The mask with the PP apparatus may be used alone or in combination with an aerosol delivery apparatus. In another embodiment, the PP apparatus is associated with a mouthpiece. The mouthpiece with the PP apparatus may be used alone or in combination with an aerosol delivery apparatus. In a further embodiment, the PP apparatus is associated with a nebulizer. The nebulizer with the PP apparatus may be used alone or in combination with a patient respiratory system interface, such as a mask or mouthpiece. In yet another embodiment, the PP apparatus is associated with a spacer chamber with an integrated actuator. The spacer chamber with the integrated actuator associated with the PP apparatus may be used alone or in combination with a mouthpiece or mask.
In another embodiment, a pressurized metered dose inhaler canister is capable of association with an aerosol holding chamber having a PP valve associated therewith. In yet a further embodiment, a pressurized metered dose inhaler canister is capable of association with an aerosol holding chamber engageable with a mouthpiece or mask having a PP valve associated therewith.
Another aspect of the invention is directed to a kit for performing positive expiratory pressure including an aerosol delivery apparatus, a mouthpiece and/or mask attachable to the output end of the aerosol delivery apparatus, and a PP apparatus. The PP apparatus may be located on the aerosol delivery apparatus or the mouthpiece and/or mask. In alter- native embodiments, the PP apparatus may be attached to the aerosol delivery apparatus or integrally formed with the apparatus. The aerosol delivery apparatus, mouthpiece, and PP valve can be combined so as to accomplish positive expiratory therapy and administration of a substance, such as, but not limited to, a medicine in aerosol form. Any aerosol delivery apparatus may be used. In further embodiments of the kit, a backpiece is included for association with an aerosol delivery apparatus. A pressurized metered dose inhaler can engage with the backpiece for delivery of a medicament.
One embodiment of a method of performing positive expiratory pressure therapy includes providing a PP apparatus with a valve that is capable of providing a continuously variable expiratory window. The method further includes performing a series of breaths. When exhalation is performed, the exhalant is directed through the continuously variable expiratory window. Performance of a therapeutic cough triggers the loosening of secretions. Upon loosening of the secretions, a substance, such as a medicament, may be provided for inhalation into the respiratory system. In an alternative embodiment of method, the PP valve may be positioned so as to provide positive inspiratory pressure upon inhalation into the apparatus.
A further aspect of another embodiment includes association of a PP apparatus associable with a mask or mouthpiece engageable with a backpiece device. The backpiece device includes a plastic or an elastomeric adapter suited to receive the mouthpiece of a pressurized metered dose inhaler.
One embodiment of a method of performing positive expiratory pressure therapy includes providing a positive expiratory pressure apparatus having a valve capable of providing a continuously variable resistance window, performing a series of breaths including inhalation and exhalation; exhaling so that the exhalant is directed through the continuously variable resistance window, performing a therapeutic cough triggering the loosening of secretions, and providing an inhaleable medicament.
Another embodiment of a method of performing positive expiratory pressure therapy includes providing a positive respiratory pressure apparatus having a valve capable of providing a continuously adjustable resistance to exhalation, where the valve is located in a mouthpiece attachable to a chamber. A patient then executes a series of therapeutic breaths, including inhalation and exhalation, wherein the exhalant is directed through the continuously adjustable resistance window, the patient performs a therapeutic cough triggering the loosening of secretions, and medicament is provided via the chamber.
According to another aspect of the invention, a method of performing positive expiratory pressure therapy in combination with providing an aerosolized medicament includes providing a positive expiratory pressure apparatus having a positive expiratory pressure valve capable of providing a continuously variable resistance window, where the valve is positionable in a mouthpiece and the mouthpiece attachable to an aerosol holding chamber. A series of therapeutic breaths, including inhalation and exhalation, are then taken where the exhalant is directed through the continuously variable resistance window. The continuously variable resistance window is preferably capable of providing a variable back pressure to the exhalant. A therapeutic cough capable of triggering the loosening of sections is performed and aerosolized medicament from the aerosol holding chamber is administered through inhalation.
One embodiment of an apparatus capable of performing positive respiratory pressure therapy in combination with providing an aerosolized medicament includes a positive respiratory pressure valve having a continuously variable resistance window; and an aerosol holding chamber having an output end, the positive respiratory pressure valve locatable at the output end.
Another embodiment of an apparatus capable of performing positive respiratory pressure therapy includes a positive respiratory pressure valve having a slide control, the slide control providing a continuously variable resistance window; and a mouthpiece, the mouthpiece having a first and a second end, the second end capable of association with the positive respiratory pressure valve.
Yet another embodiment of an apparatus capable of performing positive respiratory pressure therapy in combination with providing an aerosolized medicament includes a positive respiratory pressure valve having a continuously variable resistance window; an aerosol holding chamber having an input end and an output end, the positive respiratory pressure valve locatable at the output end; and a metered dose inhaler canister capable of association with the input end of the aerosol holding chamber.
A still further embodiment of a kit for performing positive expiratory pressure includes an aerosol holding chamber having an inlet and an outlet. A backpiece is attachable to the inlet of the aerosol holding chamber with a metered dose inhaler capable of association with the backpiece. A mouthpiece is attachable to the outlet of the aerosol holding chamber. A positive expiratory pressure valve is generally locatable at the outlet end of the aerosol holding chamber, wherein the aerosol holding chamber, backpiece, mouthpiece, and positive expiratory pressure valve can be combined so as to accomplish positive expiratory therapy and administration of an aerosolized medicament.
An additional embodiment of an apparatus capable of performing positive expiratory pressure therapy in combination with providing an aerosolized medicament includes a positive expiratory pressure valve having a continuously variable resistance window, a mouthpiece, the positive expiratory pressure valve associable with the mouthpiece, and a nebulizer having an input end and an output end, the positive expiratory pressure valve associable with the output end.
Further embodiments include a mouthpiece wherein the improvement comprises a positive pressure valve. An additional embodiment includes a nebulizer wherein the improvement comprises a positive pressure valve. Moreover, an embodiment includes an aerosol holding chamber wherein the improvement comprises a positive pressure valve. A yet further embodiment includes a pressurized metered dose inhaler wherein the improvement comprises a positive pressure valve.
The invention will best be understood by reference to the following detailed description of the preferred embodiment, taken in conjunction with the accompanying drawings. The discussion below is descriptive, illustrative and exemplary and is not to be taken as limiting the scope defined by any appended claims.
In the embodiment of
In the embodiment depicted in
The PP valve 12 may be located on or in conjunction with a mouthpiece 16. An exemplary embodiment of the mouthpiece 16 shown in
Generally, in one exemplary embodiment, the PP valve 12 may be located at or near the distal end 30 of the mouthpiece 16. Although, it is understood that the PP valve 12 may be located anywhere on the mouthpiece 1 and its location is not to be limited. In an alternative embodiment, the PP valve 12 may be located at or near the output end 20 of the aerosol delivery apparatus, such as, but not limited to, the aerosol holding chamber 14 of
In a preferred embodiment the mouthpiece 16 is formed of plastic. The plastic may be either rigid or soft. Other materials that can also be used for the mouthpiece 16 include metal or other materials known to one in the art. In the embodiment depicted in
In a further embodiment, as shown in
In the illustrated embodiment, the tab setting 46 is a uniformly molded projection from the slide control 26. In a preferred embodiment, the tab setting 46 has smooth edges for easy engagement with the finger, thumb or appendix of the user. The tab setting 46 may also have a serrated edge or any other edge known in the art. When assembled with the mouthpiece 16, the tab setting 46 projects through the mouthpiece from the tab window 48. The user of the device manipulates the tab setting 46 in such a manner as to cause, either directly or indirectly, the movement of the slide control 26 thereby varying the opening of the resistance window 28.
In the embodiment of
In the embodiment shown in
The end of the slide control 26 opposite the control arm 56 may either be provided with a finger projection 58 or may be smooth. The length of the slide control 26 extending from the tab setting 46 to the end of the control arm 56 opposite the projection 58 is generally the length of the resistance window 28. This resistance control length 60 is at least the length that the resistance window 28 can be opened allowing for exhalant to exit the window 28. In a preferred embodiment, the slide control 26 is manufactured of a plastic. The plastic may be either rigid or soft. Other materials that can also be used for the slide control 26 include metal or other materials known in the art.
In general, as shown in
An alternative embodiment of an assembly 100 for performing PEP therapy is shown in
The detent 158 located on the tab setting 146 is associated with at least one detent notch 154 as shown in
The slide control 126, as shown in
As described above, and similar to the embodiment of
Referring to
Referring to
The mouthpiece assembly 216 is connected to the output end 222 of the chamber housing 214 by placing the apertures 284 over the locking tabs 281. As with the embodiment of
A valve 278 having a valve member 279 and a valve seat 280 is shown. The valve seat 280 preferably comprises the rim of the valve and the corresponding raised lip 283 on the outlet end 222 of the chamber housing 214. The valve member has a sealing surface that preferably forms between two parallel portions, or lips, of the valve. In a preferred embodiment, the valve material seals against itself when fluid flows against a predetermined flow direction of the valve. In the embodiment shown, the valve is a duck-bill valve where the valve seat 280 is positioned axially away from the valve opening. The valve 278 defines a central open area toward the end having the valve seat. The valve member 279, shown as parallel sealing lips in
In one preferred embodiment, the duck-bill valve 278 has a central open area 274 at its base that has a diameter of approximately 26.09 millimeters (mm). The width of the lips that form the valve member 279 is approximately 21.35 mm and the angle at which the walls 285 converge is approximately 72 degrees. Also, the height of the duck-bill valve 278 measured from the upper portion 282 of the valve seat to the valve member 279 is approximately 18.8 mm. The mouthpiece 216 for containing this valve 278 preferably includes a resistance widow gap 225 having a length of 59 degrees of arcuate cut in the annular sealing ring 224, where the annular sealing ring is approximately 31.4 mm in diameter and has a height of 4.5 mm.
The operation of the apparatus will now be discussed generally with reference to the embodiments of
Exhalation by the patient results in air traveling through the mouthpiece in a direction opposite the predetermined inhalation flow path of the valve. This air, which is blocked from passage through the valve along the inhalation path, then passes along a second path through the resistance window in the mouthpiece. Also, the force of the exhaled air causes the outer portion of the valve to move away from the mouthpiece in a direction towards the chamber housing. As a result, an exhalation pathway is created between the outer portion of the valve and the mouthpiece through which the exhaled air passes out to the atmosphere or some other predetermined location. As described above, the amount of effort that exhalation requires is set by the slide control, which may be set to block the appropriate amount of the resistance window to achieve the desired resistance.
Referring specifically to the duck-bill valve embodiment of
As shown in
Although the embodiments of
In
Referring again to
Upon exhalation into the proximal end 430 of the mouthpiece 416, a positive pressure builds in the nebulizer 414 and the piston acts as a one-way valve to close off the flow of air out of the nebulizer. Now, the exhalant must travel through the one-way valve in the PP valve assembly 412, through the slide control and out the resistance window. Preferably the slide control 426 under the resistance window 428 has been set to the appropriate position for the patient so that effective PEP therapy may be provided. Although the PEP apparatus of
Although positive expiratory devices have been shown in detail, embodiments of positive inspiratory devices are also contemplated.
As discussed above, embodiments of patient respiratory system interfaces aside from the mouthpiece configurations already disclosed are contemplated. A PP apparatus 510 utilizing a mask 512 as the interface is illustrated in
Referring to
This embodiment depicts the resistance window 528 as a curved tear-drop like shape. The platform 526 is shown as a circular disc having at least one port opening 530. The port opening 530 may vary in size and shape. The opening formed for the exhalant to pass through is related to the alignment of the resistance window 528 with the port opening 530. In this embodiment, the resistance window is moveably mounted relative to a fixed slide control portion attached to the mask. Tabs 542 on the platform 526 preferably mate with tab receiving regions 544 on the end of the nosepiece section 516 to retain the platform in a fixed position relative to the mask. Moving the tear-drop shaped resistance window 528 past the part opening 530 vanes the exhalant path. In other embodiments, a plurality of resistance window openings 528 may be moved past the port 530. Alternatively, there may be a plurality of ports in the slide control 526.
As shown in
In alternative embodiments, PEP therapy maybe performed with a mouthpiece or mask having the PP valve associated with a backpiece. The mask or mouthpiece may have an extended inlet for association with the backpiece.
Asthmatic medications are commonly supplied in metered dose inhalers, frequently referred to as pressurized metered dose inhalers. Pressurized metered dose inhalers are generally cylindrical canisters with axially extending vent tubes from internal valves. When the external tube or stem of a pressurized metered dose inhaler canister is depressed it operates the internal valve to dispense a measured dose of medicine from the stem. The medicine is commonly packed in the canister with a suitable compressed gas to propel the medicine and gas from the stem or tube when the later is depressed. The medicine may be in gas, liquid, or solid form. The manufacturer or distributor of the pressurized metered dose inhaler canister generally supplies it with a substantially L-shaped adapter which receives the canister in a substantially upright position, and has a substantial horizontal outlet portion for reception in the mouth of an asthmatic patient for inhalation of the medicine.
In order to address the problem of coordination and other problems known in the art with regard to pressurized metered dose inhalers, a spacer chamber with an integrated actuator, or an aerosol holding chamber, have been used in attempts to overcome inappropriate particle size. The aerosol holding chamber is generally provided at the upstream or entering end with a flexible, resilient adapter or backpiece made of rubber or the like material. A central aperture is provided for receipt of the horizontal outlet portion of the pressurized metered dose inhaler adapter.
One embodiment provides for an improved pressurized metered dose inhaler or pressurized metered dose inhaler with an aerosol holding chamber. As shown in
Generally, a mouthpiece or mask may be associated the PP apparatus. In one configuration, an aerosol holding chamber may be attached to the mouthpiece or mask end and a metered dose inhaler may be positioned on a generally opposite end of the chamber via a backpiece. The user of the device may insert the mouthpiece into the mouth to obtain a dose of medicament. Further, the user may place the mask over the mouth and/or nose to inspire a dose of the medicament. In either situation, the mask or mouthpiece aids in the delivery of the medicament to the user.
As has been described, a method and apparatus from providing positive expiration or inhalation therapy, with or without separate aerosol generating devices, has been disclosed. In the embodiment where the positive expiratory pressure valve is located at or near the output end of the aerosol delivery apparatus, a one way inhalation valve can be located further downstream from the positive expiratory pressure valve. A mouthpiece and or mask can be affixed at or near the output end of the aerosol delivery apparatus. The positioning of the inhalation valve either upstream or downstream in respect to the positive expiratory pressure valve is well known to one skilled in the art. Further, it is envisioned that PEP therapy may be performed nasally with the positive expiratory pressure apparatus.
When the mouthpiece having the PP apparatus associated therewith is used alone to perform PEP therapy, and not in conjunction with a mechanism for the delivery of a substance, a one way inhalation valve is engageable with the mouthpiece. The inhalation valve functions so as to allow for inhalation by the patient into the mouthpiece. The exhalant of the patient is prevented from exiting via the inhalation valve and is directed to exit through the PP valve. Generally, an inhalation valve opens upon inhalation to allow a fluid, such as an aerosol, to enter a chamber or channel or the like but that closes upon exhalation to prevent exhaled fluids to enter into the chamber of the like. The drawings depict an exemplary embodiment of the one-way inhalation valve but are not to be limiting to the embodiments shown.
One aspect of the method of use of the PP apparatus can be understood by the following disclosure and reference to
The method of performing PEP therapy using the PP apparatus includes performing a series of breaths. When exhalation is performed, the exhalant is directed through the continuously variable expiratory window. Performance of a therapeutic cough triggers the loosening of secretions. Upon loosening of the secretions, a medicament may be provided for inhalation into the respiratory system. In one embodiment of PEP therapy, the user will exhale into the mouthpiece and/or mask, against the desired resistance. This is done either prior to or in combination with inhalation of the medicament. The exhaled gases exit through the resistance window. This process may be repeated as many times as prescribed by the patient's physician.
As has been described, a method and apparatus for providing positive expiration, or inhalation, pressure therapy, with or without separate aerosol generating devices, has been disclosed. The aerosol delivery apparatus with the PP apparatus may be used alone or in combination with a mask or mouthpiece. Also, an improved aerosol delivery apparatus with an integrated actuator has been shown, wherein the improvement comprises a PP valve. The discussion above is descriptive, illustrative and exemplary and is not to be taken as limiting the scope defined by any appended claims.
This application is a continuation of U.S. application Ser. No. 09/833,019, filed Apr. 11, 2001, now U.S. Pat. No. 6,557,549, which claims the benefit of U.S. Provisional Application No. 60/196,555, filed Apr. 11, 2000, wherein the entirety of each of the aforementioned applications are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
393869 | Warren | Dec 1888 | A |
2670739 | McNeill | Mar 1954 | A |
3236458 | Ramis | Feb 1966 | A |
3556122 | Laerdal | Jan 1971 | A |
3565071 | Cobb et al. | Feb 1971 | A |
3643686 | Koegel | Feb 1972 | A |
3809084 | Hansen | May 1974 | A |
3809294 | Torgeson | May 1974 | A |
3838686 | Szekely | Oct 1974 | A |
3897779 | Hansen | Aug 1975 | A |
3994421 | Hansen | Nov 1976 | A |
4174712 | Moren et al. | Nov 1979 | A |
4182366 | Boehringer | Jan 1980 | A |
4198969 | Virag | Apr 1980 | A |
4231375 | Boehringer et al. | Nov 1980 | A |
4267832 | Häkkinen | May 1981 | A |
4275722 | Sorensen | Jun 1981 | A |
4292966 | Mono et al. | Oct 1981 | A |
4298023 | McGinnis | Nov 1981 | A |
4344573 | De Felice | Aug 1982 | A |
4470412 | Nowacki et al. | Sep 1984 | A |
4496086 | Duchadeau | Jan 1985 | A |
4509515 | Altounyan et al. | Apr 1985 | A |
4635631 | Izumi | Jan 1987 | A |
4637528 | Wachinski et al. | Jan 1987 | A |
4641644 | Andersson et al. | Feb 1987 | A |
4646644 | Richmond et al. | Mar 1987 | A |
4770413 | Green | Sep 1988 | A |
4796614 | Nowacki et al. | Jan 1989 | A |
4846168 | Abiko et al. | Jul 1989 | A |
4852561 | Sperry | Aug 1989 | A |
4886057 | Nave | Dec 1989 | A |
4907583 | Wetterlin et al. | Mar 1990 | A |
4940051 | Lankinen | Jul 1990 | A |
4981295 | Belman et al. | Jan 1991 | A |
5012803 | Foley et al. | May 1991 | A |
5012804 | Foley et al. | May 1991 | A |
5033463 | Cocozza | Jul 1991 | A |
5040527 | Larson et al. | Aug 1991 | A |
5042467 | Foley | Aug 1991 | A |
5048729 | Pritchard | Sep 1991 | A |
5109840 | Daleiden | May 1992 | A |
5178138 | Walstrom et al. | Jan 1993 | A |
5193529 | Labaere | Mar 1993 | A |
5241954 | Glenn | Sep 1993 | A |
5250287 | Cocozza | Oct 1993 | A |
5280784 | Kohler | Jan 1994 | A |
5297543 | Larson et al. | Mar 1994 | A |
5309900 | Knoch et al. | May 1994 | A |
5312046 | Knoch et al. | May 1994 | A |
5357951 | Ratner | Oct 1994 | A |
5385140 | Smith | Jan 1995 | A |
5427089 | Kraemer | Jun 1995 | A |
5456249 | Kirk | Oct 1995 | A |
5458136 | Jaser et al. | Oct 1995 | A |
5461695 | Knoch | Oct 1995 | A |
5477849 | Fry | Dec 1995 | A |
5479920 | Piper et al. | Jan 1996 | A |
5497765 | Praud et al. | Mar 1996 | A |
5497872 | Pennino | Mar 1996 | A |
5501214 | Sabo | Mar 1996 | A |
5505194 | Adjei et al. | Apr 1996 | A |
5549102 | Lintl et al. | Aug 1996 | A |
5562093 | Gerson | Oct 1996 | A |
5575282 | Knoch et al. | Nov 1996 | A |
5596982 | Blaha-Schnabel | Jan 1997 | A |
5598839 | Niles et al. | Feb 1997 | A |
5617844 | King | Apr 1997 | A |
5629032 | Pennino | May 1997 | A |
5645049 | Foley et al. | Jul 1997 | A |
5647345 | Saul | Jul 1997 | A |
5657853 | Pennino | Aug 1997 | A |
5658221 | Hougen | Aug 1997 | A |
5676130 | Gupte et al. | Oct 1997 | A |
5724959 | McAughey et al. | Mar 1998 | A |
5724962 | Vidgren et al. | Mar 1998 | A |
5738087 | King | Apr 1998 | A |
5740966 | Blaha-Schnabel | Apr 1998 | A |
5755221 | Bisgaard | May 1998 | A |
5765553 | Richards et al. | Jun 1998 | A |
5775320 | Patton et al. | Jul 1998 | A |
5816240 | Komesaroff | Oct 1998 | A |
5840279 | Narodylo et al. | Nov 1998 | A |
5848588 | Foley et al. | Dec 1998 | A |
5881718 | Mortensen et al. | Mar 1999 | A |
5890998 | Hougen | Apr 1999 | A |
5896857 | Hely et al. | Apr 1999 | A |
5899832 | Hougen | May 1999 | A |
5925831 | Storsved | Jul 1999 | A |
5957389 | Wunderlich et al. | Sep 1999 | A |
6000394 | Blaha-Schnabel et al. | Dec 1999 | A |
6026807 | Puderbaugh et al. | Feb 2000 | A |
6026808 | Armer et al. | Feb 2000 | A |
6026809 | Abrams et al. | Feb 2000 | A |
6039042 | Sladek | Mar 2000 | A |
6044841 | Verdun et al. | Apr 2000 | A |
6085741 | Becker | Jul 2000 | A |
6089105 | Ricciardelli | Jul 2000 | A |
6106479 | Wunderlich | Aug 2000 | A |
6123075 | Kirk | Sep 2000 | A |
6138673 | Shepherd | Oct 2000 | A |
6176237 | Wunderlich et al. | Jan 2001 | B1 |
6228346 | Zhang et al. | May 2001 | B1 |
6240917 | Andrade | Jun 2001 | B1 |
6257231 | Shick et al. | Jul 2001 | B1 |
6293279 | Schmidt et al. | Sep 2001 | B1 |
6345617 | Engelbreth et al. | Feb 2002 | B1 |
6367471 | Genosar et al. | Apr 2002 | B1 |
6412481 | Bienvenu et al. | Jul 2002 | B1 |
6435177 | Schmidt et al. | Aug 2002 | B1 |
6464388 | Ligouzat | Oct 2002 | B2 |
6481438 | Gallem et al. | Nov 2002 | B1 |
6513519 | Gallem | Feb 2003 | B2 |
6513727 | Jaser | Feb 2003 | B1 |
6514177 | Brugger et al. | Feb 2003 | B1 |
6557549 | Schmidt et al. | May 2003 | B2 |
6581598 | Foran et al. | Jun 2003 | B1 |
6606990 | Stapleton et al. | Aug 2003 | B2 |
6631721 | Salter et al. | Oct 2003 | B1 |
D483860 | Knoch | Dec 2003 | S |
6679251 | Gallem et al. | Jan 2004 | B1 |
6679252 | Sladek | Jan 2004 | B2 |
6848443 | Schmidt et al. | Feb 2005 | B2 |
6962151 | Knoch et al. | Nov 2005 | B1 |
6983747 | Gallem et al. | Jan 2006 | B2 |
7013896 | Schmidt | Mar 2006 | B2 |
7059320 | Feiner et al. | Jun 2006 | B2 |
7077126 | Kummer et al. | Jul 2006 | B2 |
7131440 | Sonntag | Nov 2006 | B2 |
7562656 | Gallem et al. | Jul 2009 | B2 |
20010013341 | Gallem | Aug 2001 | A1 |
20010054421 | Jaser et al. | Dec 2001 | A1 |
20020005196 | Brugger | Jan 2002 | A1 |
20020056448 | Stapleton et al. | May 2002 | A1 |
20030037785 | Sonntag | Feb 2003 | A1 |
20030037788 | Gallem et al. | Feb 2003 | A1 |
20030205226 | Gallem et al. | Nov 2003 | A1 |
20040089295 | Gallem et al. | May 2004 | A1 |
20040094148 | Lulla et al. | May 2004 | A1 |
20040250816 | Kummer et al. | Dec 2004 | A1 |
20050039741 | Gallem et al. | Feb 2005 | A1 |
20050056274 | Kunschir | Mar 2005 | A1 |
20050224076 | Pfichner et al. | Oct 2005 | A1 |
20050244339 | Jauernig et al. | Nov 2005 | A1 |
20060011196 | Gallem et al. | Jan 2006 | A2 |
20060048772 | Borgschulte | Mar 2006 | A1 |
20060054166 | Knoch et al. | Mar 2006 | A1 |
20060057073 | Lintz et al. | Mar 2006 | A1 |
20060065267 | Tran et al. | Mar 2006 | A1 |
20060102172 | Feiner et al. | May 2006 | A1 |
20060102178 | Feiner et al. | May 2006 | A1 |
20060162723 | Selzer et al. | Jul 2006 | A1 |
20060207591 | Gallem et al. | Sep 2006 | A1 |
20060213503 | Borgschulte et al. | Sep 2006 | A1 |
20060254578 | Boehm et al. | Nov 2006 | A1 |
20060289002 | Hetzer et al. | Dec 2006 | A1 |
Number | Date | Country |
---|---|---|
2072544 | Dec 1992 | CA |
0009667 | Apr 1980 | EP |
0015247 | Dec 1982 | EP |
0134847 | Mar 1985 | EP |
0 372 148 | Jun 1990 | EP |
0372148 | Jun 1990 | EP |
0289563 | May 1991 | EP |
0514085 | Nov 1992 | EP |
0 520 571 | Dec 1992 | EP |
0347779 | May 1994 | EP |
0475257 | Jun 1994 | EP |
0 678 306 | Oct 1995 | EP |
678306 | Oct 1995 | EP |
0548152 | Jul 1996 | EP |
0514085 | Jul 1997 | EP |
0820780 | Jan 1998 | EP |
0 520 571 | Sep 1998 | EP |
0585379 | Sep 1998 | EP |
0 938 908 | Sep 1999 | EP |
938908 | Sep 1999 | EP |
1 358 901 | Nov 2003 | EP |
975754 | Nov 1964 | GB |
1017032 | Jan 1966 | GB |
2000555 | Jan 1979 | GB |
2299512 | Oct 1996 | GB |
55-40595 | Mar 1980 | JP |
0 548 152 | Jun 1993 | JP |
06-178954 | Jun 1994 | JP |
WO 9100117 | Jan 1991 | WO |
WO 9220391 | Nov 1992 | WO |
WO 9311817 | Jun 1993 | WO |
WO 9520414 | Aug 1995 | WO |
WO 9632149 | Oct 1996 | WO |
WO 9701365 | Jan 1997 | WO |
WO 9731668 | Sep 1997 | WO |
WO 9826827 | Jun 1998 | WO |
WO 9100117 | Jan 1999 | WO |
WO 9916490 | Apr 1999 | WO |
WO 0027455 | May 2000 | WO |
WO 0059565 | Oct 2000 | WO |
WO 0176671 | Oct 2001 | WO |
Number | Date | Country | |
---|---|---|---|
60196555 | Apr 2000 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09833019 | Apr 2001 | US |
Child | 10389257 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10389257 | Mar 2003 | US |
Child | 11655039 | US |